Pediatric Cryptosporidiosis Workup
- Author: Jaya Sureshbabu, MBBS, DCh, MRCPCH(UK), MRCPI(Paeds), MRCPS(Glasg), DCH(Glasg); Chief Editor: Russell W Steele, MD more...
Imaging Studies
Imaging studies are not indicated as a first-line diagnostic approach in cryptosporidiosis.
Abdominal radiography and computed tomography (CT) scanning are nonspecific and may reveal distended loops of bowel, air-fluid levels, and disrupted bowel motility.
When indicated, as guided by symptoms, ultrasonography or CT scanning may reveal an enlarged gallbladder with a thickened wall, dilated or irregular intrahepatic and extrahepatic biliary ducts, and a normal or stenotic distal common bile duct.
In cases of respiratory involvement, chest radiography is unremarkable, with modest infiltrates or increased bronchial markings.
Cholangiography may reveal beading of the common bile duct or papillary stenosis.
Approach Considerations
Cryptosporidium can be difficult. Most often, stool specimens are examined microscopically using different techniques (eg, acid-fast staining, direct fluorescent antibody [DFA], and/or enzyme immunoassays for detection of Cryptosporidium species antigens). Go to Cryptosporidiosis for complete information on this topic.
Stool Examination
Collection
Follow collection recommendations and precautions on routine parasitologic examination of stools. For immunodiagnostic assay kits, follow the manufacturer’s instructions.
Transport
If immediate examination is not possible, use one of several preservatives, such as 5-10% buffered formalin, merthiolate-iodine-formalin (MIF), or SAF. Refrigerate unpreserved specimens to delay deterioration. Do not freeze specimens.
Processing
Unconcentrated, fresh specimens can be examined by wet mount preparations. Concentration by the formalin ethyl acetate method is preferable. Optimal centrifugation time and speed, 10 minutes at 500 X, are critical for concentrating Cryptosporidium oocysts. Commercial fecal concentration tubes are available that decrease processing time and supplies needed for concentrating specimens (eg, Fecal Parasite Concentrator, Evergreen Scientific). PVA-preserved specimens are not acceptable for modified acid-fast staining for detection of Cryptosporidium.
Examination techniques
Modified acid-fast staining procedure is useful for the identification of oocysts of the coccidian species (Cryptosporidium, Cystoisospora, and Cyclospora), which may be difficult to detect with routine stains, such as trichrome. Cryptosporidium species stain a pinkish-red color. The background should stain uniformly green. Unlike the Ziehl-Neelsen modified acid-fast stain, this stain does not require the heating of reagents for staining. (See the images below.)
Cryptosporidium parvum oocysts stained with modified acid-fast. Against a blue-green background, the oocysts stand out in a bright red stain. Image courtesy of CDC DPDx parasite image library.
Cryptosporidium species oocysts stained with modified acid-fast. A monoclonal antibody-based fluorescein conjugated stain for oocysts in stool is commercially available. An enzyme immunoassay (EIA) to detect antigen in stool is also commercially available and is the most specific, reliable test that is widely available.[15]
Specimen examination
Concentrated sediment of fresh (within 30 min after passage of stools) or formalin-preserved stool may be used. Other types of clinical specimens, such as duodenal fluid, bile, and pulmonary samples (induced sputum, bronchial wash, biopsies) may also be stained. The sucrose flotation method or formalin ethyl acetate method is used to concentrate stool before staining with a modified Kinyoun acid-fast stain, because routine laboratory examination of stool for ova and parasites does not detect Cryptosporidium.[2, 4] This technique stains oocysts pink or red, whereas fecal debris or yeast assumes the color of blue or green counterstain.
Because shedding may be intermittent, examine at least 3 stool specimens collected on separate days before considering the test results negative. Fecal leukocytes are not found in stool specimens because it does not invade below the epithelial layer of the mucosa.
Oocysts are small (4-6 μm in diameter) and can be missed without a very careful examination of the slide.
GI biopsy specimens can be used instead of stool specimens. A high concentration of oocysts is seen in the jejunum.
Electron microscopy of stool or biopsy specimens can also be performed for direct visualization of oocysts.
For research purposes and for species identification, polymerase chain reaction (PCR) assays are used.
Serologic detection of specific anti-Cryptosporidium antibodies is primarily used as a research or epidemiologic tool.
GI or Liver Biopsy
GI or liver biopsy may be indicated in cases of diagnostic uncertainty. Different parts of the intestinal tract may be affected. Liver biopsy findings may reveal the organism attached to bile duct epithelial cells. Concurrent infection with cytomegalovirus (CMV), Enterobacter cloacae, and microsporidia is common.
Bronchoalveolar Lavage and Lung Biopsy
In patients with related symptoms, bronchoalveolar lavage or lung biopsy findings may reveal the parasite in lavage fluid, in brush biopsy specimens, attached to the surface of bronchial mucosal cells, or in macrophages. In most instances, another pulmonary pathogen, such as CMV or Pneumocystis carinii, is concurrently detected; however, in a series of 4 patients infected with HIV, Cryptosporidium was the only pathogen identified in the respiratory tract. Clear association with intestinal cryptosporidiosis or diarrhea has not been shown in these cases.
Histologic Findings
Villous atrophy with blunting, epithelial flattening, and an increase in lamina propria lymphocytes are seen in patients with persistent cryptosporidiosis. In patients with heavier infection, crypt hyperplasia and marked infiltration with lymphocytes, plasma cells, and neutrophils are also noted. Biopsy samples of the biliary ducts may reveal the parasites.
Flynn PM. Cryptosporidium parvum. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatrics. New York, NY: Churchill Livingstone; 1997.
White C Jr. Cryptosporidiosis. In: Mandell GL, Bennett JE, Doilin R. Principles and practice of Infectious Diseases. Vol 2. 6th. Philadelphia, Pennsylvania: Elsivier Churchill Livingstone; 2005:280.
Huang DB, Chappell C, Okhuysen PC. Cryptosporidiosis in children. Semin Pediatr Infect Dis. Oct 2004;15(4):253-9. [Medline].
Committee on Infectious Diseases, American Academy of Pediatrics. Cryptosporidiosis. In: Pickering LK, Baker CJ, Long S, McMillan JA. Red book. 27th. Elk Grove Village, IL: AAP; 2006:270-272.
Meinhardt PL, Casemore DP, Miller KB. Epidemiologic aspects of human cryptosporidiosis and the role of waterborne transmission. Epidemiol Rev. 1996;18(2):118-36. [Medline].
Fayer R, Morgan U, Upton SJ. Epidemiology of Cryptosporidium: Transmission,detection and identification. Int J Parasitol. 2000;30:1305-1322.
Cryptosporidiosis surveillance--United States, 2003-2005.Division of Parasitic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, CDC [database online]. Atlanta, GA 30333: Centers for Disease Control and Prevention (CDC); Updated 2007 Sep 7.
MacKenzie WR, Schell WL, Blair KA, Addiss DG, Peterson DE, Hoxie NJ, et al. Massive outbreak of waterborne cryptosporidium infection in Milwaukee, Wisconsin: recurrence of illness and risk of secondary transmission. Clin Infect Dis. Jul 1995;21(1):57-62. [Medline].
Semenza JC, Nichols G. Cryptosporidiosis surveillance and water-borne outbreaks in Europe. Euro Surveill. May 1 2007;12(5):E13-4. [Medline].
Cooper DL, Verlander NQ, Smith GE, Charlett A, Gerard E, Willocks L, et al. Can syndromic surveillance data detect local outbreaks of communicable disease? A model using a historical cryptosporidiosis outbreak. Epidemiol Infect. Feb 2006;134(1):13-20. [Medline]. [Full Text].
Navin TR, Hardy AM. Cryptosporidiosis in patients with AIDS. J Infect Dis. Jan 1987;155(1):150. [Medline].
Abubakar I, Aliyu SH, Arumugam C, Usman NK, Hunter PR. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br J Clin Pharmacol. Apr 2007;63(4):387-93. [Medline]. [Full Text].
Wolska-Kusnierz B, Bajer A, Caccio S, Heropolitanska-Pliszka E, Bernatowska E, Socha P, et al. Cryptosporidium infection in patients with primary immunodeficiencies. J Pediatr Gastroenterol Nutr. Oct 2007;45(4):458-64. [Medline].
Cello JP. Acquired immunodeficiency syndrome cholangiopathy: spectrum of disease. Am J Med. May 1989;86(5):539-46. [Medline].
Weintraub JM. Improving cryptosporidium testing methods: a public health perspective. J Water Health. 2006;4 Suppl 1:23-6. [Medline].
Soave R. Treatment strategies for cryptosporidiosis. Ann N Y Acad Sci. 1990;616:442-51. [Medline].
Ayuo PO. Human cryptosporidiosis: a review. East Afr Med J. Feb 2009;86(2):89-93. [Medline].
Juranek DD. Cryptosporidiosis: sources of infection and guidelines for prevention. Clin Infect Dis. Aug 1995;21 Suppl 1:S57-61. [Medline].
Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis. Apr 15 2005;40(8):1173-80. [Medline].
Smith NH, Cron S, Valdez LM, Chappell CL, White AC Jr. Combination drug therapy for cryptosporidiosis in AIDS. J Infect Dis. Sep 1998;178(3):900-3. [Medline].
Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. Sep 4 2009;58:1-166. [Medline]. [Full Text].
Hicks P, Zwiener RJ, Squires J, Savell V. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. J Pediatr. Aug 1996;129(2):297-300. [Medline].
Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev. Jan 24 2007;CD004932. [Medline].

